Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society

ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizures
No impairment in cognitive performance or changes in psychological health were observed

DEVON, Pa., Dec. 05, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced additional results from Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose studies of ZYN002 cannabidiol (CBD) gel. These results, which assessed safety, tolerability, and effects on cognition and mood, of ZYN002 CBD gel in both healthy adults and adult epilepsy patients with focal seizures, were reported at the 70th Annual Meeting of the American Epilepsy Society (AES) in Houston, Texas. ZYN002 CBD gel is a patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery in development for the treatment of epilepsy, osteoarthritis and Fragile X syndrome.

“In these first human clinical studies of CBD via transdermal delivery, we are very encouraged that results further demonstrated that ZYN002 CBD gel is safe and well-tolerated in both healthy subjects and adult epilepsy patients with focal seizures across a wide range of doses and concentrations,” said Armando Anido, Chairman and CEO of Zynerba. “Further, we did not observe any difference in cognitive performance or mood changes after treatment with ZYN002 CBD gel. Enrollment in our STAR 1 clinical trial in adult epilepsy patients with focal seizures is continuing and we remain on track to report top-line results in the first half of 2017.”

Click here to read the full press release.


©2017 PACT All Rights Reserved